Skip to content

[BrainConnexion] - Neurodevice Phase I Trial

Neurodevice Phase I: Wireless Implantable Neurodevice Microsystem for Neuroprosthesis and Neuroscience

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03811301
Enrollment
5
Registered
2019-01-22
Start date
2017-11-21
Completion date
2023-08-27
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis, Locked-in Syndrome, Motor Neuron Disease, Muscular Dystrophies, Spinal Cord Injuries, Tetraplegia, Tetraplegia/Tetraparesis

Brief summary

This study aims to evaluate the safety of a wireless implantable neurodevice microsystem in tetraplegic patients, as well as the efficacy of the electrodes for long-term recording of neural activities and the successful control of an external device.

Detailed description

The goal of this study is to develop a miniaturized wireless implantable neurodevice microsystem that records and transmits signals from the motor cortex of tetraplegic patients, bypassing the damaged nervous tissue, to control an external assistive device that restores some form of independence to patients in terms of communication or mobility.

Interventions

DEVICEBrainConnexion

A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.

Sponsors

Institute of Microelectronics
CollaboratorUNKNOWN
Institute of Molecular and Cell Biology
CollaboratorUNKNOWN
Institute for Infocomm Research
CollaboratorOTHER
Nanyang Technological University
CollaboratorOTHER
National Neuroscience Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 21 years old and older 2. Tetraparesis 3. Written informed consent obtained from the patient or legal representative (in the event where the patient is unable to provide consent) prior to entry into the study in accordance with local EC/IRB regulations and/or other application regulations for surrogate consent. 4. Able to perform the pre-operation Brain Computer Interface training as judged by the research team.

Exclusion criteria

1. Significant medical co-morbidities e.g. cardiac disease 2. Bleeding disorders 3. Any contraindication to surgery 4. Other concomitant intracranial pathologies 5. History of seizures or epilepsy disorder 6. Complications of coagulopathy 7. Surgically unfit 8. Significant psychological issues e.g. Depression 9. Poor psychological support 10. Pregnancy 11. No means of communication 12. Any disease, in the opinion of the Investigator, that is unstable or which could jeopardise the safety of the patient If applicable, psychological assessment may be performed prior to selection as the implantation process will be a long a stressful event, requiring a significant degree of patient cooperation and resilience.

Design outcomes

Primary

MeasureTime frameDescription
The number of serious adverse events (SAEs) and adverse events (AEs) reported per patient 12 months post-implantation.6 months post-implantThe primary objective of this study is to determine the safety of the device. This will be assessed based on the number of SAEs and AEs reported for each patient during the 12 months post-implantation evaluation. This measure will considered a success if the device is not removed for safety reasons within 12-months after implantation.

Secondary

MeasureTime frameDescription
The signal quality of the electrodes for long-term recording of neural signals.Day 1 to Day 365 post-implantSignal quality will be measured by the number of channels with identifiable single units tracked across each day for 12 months.
Decoding accuracy per training session.Day 1 to Day 365 post-implantDecoding accuracy will be measured in percentage (%).
Number of successful trials per sessionDay 1 to Day 365 post-implantThe number of successful trials per training session will be measured in percentage (%).
Time taken to complete each trial per sessionDay 1 to Day 365 post-implantThis will be measured in seconds (s).

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026